Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII) (SLATEII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03315013
Recruitment Status : Active, not recruiting
First Posted : October 19, 2017
Last Update Posted : September 27, 2018
Sponsor:
Collaborators:
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Sydney Rosen, Boston University

Brief Summary:

In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for HIV. In sub-Saharan Africa, where most HIV patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications (ARVs). Among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for HIV is dispensed an initial supply of medications. Simpler, more efficient, accelerated algorithms for ART initiation are needed, including strategies for rapid initiation in patients with symptoms of tuberculosis, most of whom do not have active TB.

In July 2017, the original SLATE study (SLATE I) completed enrollment in South Africa. One of the most striking findings of the study so far is the large proportion of patients who "screened out" of the SLATE algorithm and were referred for additional services rather than started on ART immediately. Among 298 patients assigned to the intervention arm and evaluated for immediate treatment eligibility under the SLATE algorithm, 149 (50%) screened out, two thirds of these (100/149) due to symptoms of TB. The vast majority of the TB suspects (93/100, 93%) tested negative for active TB.

The SLATE II study will revise the original SLATE algorithm to provide a pathway for immediate ART initiation for some patients with TB symptoms. Under SLATE II, patients with TB symptoms will be clinically evaluated by the study nurse and will receive a urine point of care LAM (lipoarabinomannan antigen of mycobacteria) test. Those with milder symptoms and a negative LAM test will be offered immediate ART. Those with more serious symptoms and/or a positive LAM test will be asked to return the next day to receive TB test results and either immediate ART or TB treatment. All intervention arm patients (symptomatic and asymptomatic) will be asked for a sputum sample for Xpert testing, and positives will be contacted on the next day. The SLATE II algorithm will also incorporate other improvements identified from SLATE I.


Condition or disease Intervention/treatment Phase
HIV/AIDS Antiretroviral Therapy Procedure: SLATE II Not Applicable

Detailed Description:

SLATE II is be a pragmatic, individually randomized evaluation to determine the effectiveness of the revised algorithm in increasing ART initiation, compared to standard care, among non-pregnant adult patients. Six hundred HIV-infected adult patients not yet on ART will be enrolled during a routine clinic visit and randomized to receive the intervention or standard care. Patients in the intervention arm will be administered a revised version of the SLATE screens, including the TB add-on; those found eligible under the algorithm will be offered immediate treatment initiation, while those who are not eligible will be referred for standard clinic care. Patients in the standard arm will be referred for ART initiation under standard clinic procedures. All care after the initial visit will be by the clinic under standard care. Primary outcomes will be ART initiation within 7 days of study enrollment and viral suppression within 8 months of study enrollment.

The study is being conducted at three healthcare facilities (clinics) in South Africa. In September 2017, the South African National Department of Health instructed all clinics to offer same-day ART initiation to eligible patients but provided little guidance on determining eligibility. SLATE II will help to create such guidance. If successful, it will improve on the SLATE approach to collecting and interpreting a minimum set of patient data that will avoid delaying treatment initiation for the majority of patients who are eligible for immediate ART, while deferring initiation in the minority who should not start immediately.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Evaluation of a Revised, Simplified Clinical Algorithm for Identifying Patients Eligible for Immediate Initiation of Antiretroviral Therapy for HIV (SLATEII)
Actual Study Start Date : March 14, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: SLATE
The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
Procedure: SLATE II
The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
Other Name: Revised Simplified Algorithm for Treatment Eligibility

No Intervention: Standard
The standard arm will be referred to standard care after study enrollment.



Primary Outcome Measures :
  1. Proportion of patients initiated on ART [ Time Frame: 7 days after study enrollment ]
    % of enrolled patients initiated onto ART within one week of study enrollment, which may occur at HIV diagnosis or at a pre-ART follow-up visit

  2. Proportion of patients initiated on ART and alive, in care, and retained [ Time Frame: 8 months after study enrollment ]
    Proportion of enrolled patients initiated on ART within 28 days of study enrollment and retained in care 8 months after study enrollment, as indicated by a clinic visit no more than 7 months after ART initiation


Secondary Outcome Measures :
  1. Proportion of TB suspects initiated on ART within 14 days of study enrollment [ Time Frame: 14 days after study enrollment ]
    Proportion of TB suspects initiated on ART within 14 days of study enrollment

  2. Proportions of patients initiated on ART within 1, 14, and 28 days of study enrollment [ Time Frame: 28 days after study enrollment ]
    Proportions of patients initiated on ART within 1, 14, and 28 days of study enrollment

  3. Proportions of all patients and of TB suspects who initiate ART and are virally suppressed eight months after having an HIV test or enrolling in HIV care [ Time Frame: 8 months after study enrollment ]
    Viral suppression stratified by TB symptom status at baseline

  4. Proportions of all patients and of TB suspects who initiate ART and are alive, in care, and retained on ART 14 months after having an HIV test or enrolling in HIV care [ Time Frame: 14 months after study enrollment ]
    Retention 12 months after enrollment, allowing 1 month for initiation and 1 month for making and recording data from 12-month visit.

  5. Proportions of HIV-positive patients presenting at study clinics and not yet on ART who are eligible and ineligible for immediate initiation using SLATE algorithm criteria [ Time Frame: 1 day after study enrollment ]
    Patients who screen in and screen out of algorithm in intervention arm

  6. Reasons for ineligibility for immediate initiation [ Time Frame: 1 day after study enrollment ]
    Reasons for ineligibility for immediate initiation, among those found ineligible in the intervention arm

  7. Median time to ART initiation (days) for each arm [ Time Frame: 28 days after study enrollment ]
    Median and IQR time to ART initiation (days) for each arm

  8. Adverse events [ Time Frame: 1, 7, 14, and 28 days after enrollment; 8 and 14 months after enrollment ]
    Frequency and types of adverse events reported in medical records after ART initiation for each follow up period

  9. Patient preferences [ Time Frame: 1 day after enrollment ]
    Patient self-reported preferences on the speed and timing of ART initiation, from questionnaires

  10. LAM test results [ Time Frame: 1 day after enrollment ]
    Proportion of symptomatic patients who test positive for TB using the LAM test

  11. Xpert test results [ Time Frame: 1 week after enrollment ]
    Proportions of symptomatic and asymptomatic patients who test positive for TB using Xpert MTB/RIF, among those able to produce a sputum sample

  12. Costs to patients [ Time Frame: 14 months after study enrollment (end of followup) ]
    Costs to patients of ART initiation under standard and intervention procedures

  13. Costs to providers [ Time Frame: 14 months after study enrollment (end of followup) ]
    Costs to providers of ART initiation under standard and intervention procedures

  14. Differences from SLATE I [ Time Frame: 14 months after study enrollment (end of followup) ]
    Comparison of results of SLATE II study to SLATE I study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (>18 years) (initiating children and adolescents on ART is likely to require additional information and adherence support, making the SLATE algorithm less applicable to pediatric populations)
  • Confirmed HIV-positive test result at any time (may have been diagnosed previously)
  • Self-report that patient is not currently on ART and has not been prescribed ART in the past three months
  • Presented at the study clinic for any HIV-related reason or other reason that led to referral for HIV testing or care

Exclusion Criteria:

  • Pregnant (pregnancy is an exclusion criterion because treatment guidelines for pregnant women differ from those for non-pregnant adults; most pregnant women are diagnosed with HIV and initiated on ART in antenatal clinics, not general adult HIV clinics)
  • Not intending to return to this clinic for further HIV care in the coming year (i.e. intends to seek further care somewhere else)
  • Not willing to be traced by phone or in person for follow-up care if test results received after the enrollment visit indicate that further care is needed
  • Not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff
  • Not willing or able to provide written informed consent to participate in the study
  • Previously enrolled in the same study or the SLATE I study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03315013


Locations
Layout table for location information
South Africa
Health Economics and Epidemiology Research Office
Johannesburg, Gauteng, South Africa
Sponsors and Collaborators
Boston University
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation
Investigators
Layout table for investigator information
Principal Investigator: Sydney B Rosen Boston University
  Study Documents (Full-Text)

Documents provided by Sydney Rosen, Boston University:
Study Protocol  [PDF] October 7, 2017


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sydney Rosen, Professor, BUSPH, Boston University
ClinicalTrials.gov Identifier: NCT03315013     History of Changes
Other Study ID Numbers: H-37010
OPP1136158 ( Other Grant/Funding Number: Bill and Melinda Gates Foundation )
4852 ( Registry Identifier: NHREC South Africa )
171011 ( Other Identifier: HREC (Medical) Wits University )
First Posted: October 19, 2017    Key Record Dates
Last Update Posted: September 27, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: After protocol closure, dis-identified data generated by the study will be shared on Dryad. Data from patients' medical records do not belong to the study and cannot be shared but may be available on request from the study sites.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: After protocol closure, which will occur approximately one year after all study outcomes have been reached.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sydney Rosen, Boston University:
Antiretroviral therapy initiation
Sub-Sahara Africa
ART

Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents